Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.

[1]  D. Bernardo,et al.  Is right-sided colon cancer different to left-sided colorectal cancer? - a systematic review. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  A. Sklan.  2014 ASCO Annual Meeting. , 2014, The Lancet. Oncology.

[3]  S. Friend,et al.  Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes. , 2014 .

[4]  W. Scheithauer,et al.  Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. , 2014 .

[5]  M. Stauch,et al.  Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial , 2014, Journal of Cancer Research and Clinical Oncology.

[6]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[7]  Lan-Lan Smith,et al.  2013 ASCO Annual Meeting , 2013 .

[8]  A. Powell,et al.  The relationship between tumour site, clinicopathological characteristics and cancer‐specific survival in patients undergoing surgery for colorectal cancer , 2012, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[9]  S. Kropf,et al.  Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma. , 2012, Pathology, research and practice.

[10]  J. L. Tang,et al.  PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J. Mariadason,et al.  PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. , 2012, Clinical colorectal cancer.

[12]  P. Jess,et al.  Possible better long-term survival in left versus right-sided colon cancer - a systematic review. , 2012, Danish medical journal.

[13]  Elena A. Manilich,et al.  BRAF Mutations in Colorectal Cancer Are Associated With Distinct Clinical Characteristics and Worse Prognosis , 2012, Diseases of the colon and rectum.

[14]  Maureen A. Smith,et al.  Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Suttie,et al.  Outcome of right‐ and left‐sided colonic and rectal cancer following surgical resection , 2011, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[16]  Á. Theodórs,et al.  Colon cancer in Iceland—A nationwide comparative study on various pathology parameters with respect to right and left tumor location and patients age , 2010, International journal of cancer.

[17]  L. Terracciano,et al.  Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. , 2010, International journal of oncology.

[18]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[19]  H. Lippert,et al.  Comparison of 17,641 Patients With Right- and Left-Sided Colon Cancer: Differences in Epidemiology, Perioperative Course, Histology, and Survival , 2010, Diseases of the colon and rectum.

[20]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[21]  N. Ahuja,et al.  Is There a Difference in Survival Between Right- Versus Left-Sided Colon Cancers? , 2008, Annals of Surgical Oncology.

[22]  Jun Kato,et al.  Differences between right‐ and left‐sided colon cancer in patient characteristics, cancer morphology and histology , 2008, Journal of gastroenterology and hepatology.

[23]  Dongsheng Tu,et al.  Cetuximab for the treatment of colorectal cancer. , 2007, The New England journal of medicine.

[24]  Leopoldo Sarli,et al.  Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis , 2007, International Journal of Colorectal Disease.

[25]  George W. Wright,et al.  Distinguishing right from left colon by the pattern of gene expression. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[26]  B. Iacopetta.  Are there two sides to colorectal cancer? , 2002, International journal of cancer.

[27]  A. Lindblom.  Different mechanisms in the tumorigenesis of proximal and distal colon cancers , 2001, Current opinion in oncology.

[28]  A. Jirásek,et al.  Different expression of some molecular markers in sporadic cancer of the left and right colon. , 2000, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[29]  D. Smith,et al.  C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas. , 1996, European journal of cancer.

[30]  J. Bufill,et al.  Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. , 1990, Annals of internal medicine.

[31]  M. Delorenzi,et al.  Proximal and distal colon tumors as distinct biologic entities with different prognoses. , 2013 .

[32]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.